FDA clears Misonix's 3-in-1 ultrasonic surgery system

FDA Building
Misonix plans to begin commercialization in July and hopes the Nexus system will serve as a base for future solutions and add-ons. (FDA)

Ultrasonic surgical tool manufacturer Misonix has received clearance from the FDA for its new Nexus system, which combines the features of the company’s three existing handheld offerings into one platform.

That includes BoneScalpel, a precision, oscillating tool designed for millimeter-wide cuts in bone while sparing the surrounding soft tissue. Meanwhile, its SonicOne attachment provides a debridement tool for cleaning wounds and removing damaged tissue or bacterial biofilms during surgery.

The SonaStar ultrasonic aspirator is used to remove more-targeted tissues, such as tumors. It also includes bone-sculpting tips and a range of deep-access and laparoscopic probes.

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

Farmingdale, New York-based Misonix plans to begin its U.S. commercialization of the combined Nexus platform in July and hopes it will serve as a base for future solutions. It also includes increased power, a touchscreen display and RF capabilities for use in general surgery procedures.

RELATED: TransEnterix granted CE mark for ultrasonic robotic surgery tech

“Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets,” Misonix President and CEO Stavros Vizirgianakis said in a statement.

“Nexus provides us with a unique opportunity to leverage our robust consignment business model, further drive the sale of consumables competitively, and extend our ability to cross-sell into multiple physician specialties,” Vizirgianakis added.

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

Novartis has teamed up with smart inhaler developer Propeller Health to co-package and ship its digital medication-tracking platform.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.